Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Mitochondrial Membranes01:45

Mitochondrial Membranes

17.6K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
17.6K
Mitochondria01:37

Mitochondria

21.2K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.2K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induced pluripotent stem cells: a tool for modeling Parkinson's disease.

Trends in neurosciences·2022
Same author

The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2022
Same author

Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer's disease.

Nature communications·2022
Same author

Magnetic Resonance Imaging of Malformations of Cortical Development-A Comprehensive Review.

World neurosurgery·2021
Same author

Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model.

Neuropathology and applied neurobiology·2021
Same author

Isotope-reinforced polyunsaturated fatty acids improve Parkinson's disease-like phenotype in rats overexpressing α-synuclein.

Acta neuropathologica communications·2020

Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.4K

Mitochondrial dysfunction in Parkinson's disease.

Anindita Bose1, M Flint Beal2

  • 1Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York City, New York, USA. anb2055@med.cornell.edu.

Journal of Neurochemistry
|August 23, 2016
PubMed
Summary

Mitochondrial dysfunction is a key factor in Parkinson's disease (PD) pathogenesis, affecting neurons and contributing to disease progression. This review details mechanisms of mitochondrial dysfunction in PD and explores therapeutic strategies.

Keywords:
MAMDJ1HTRA2PINK1VPS35α-synuclein

More Related Videos

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

17.5K
Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry
08:19

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Published on: May 5, 2022

2.9K

Related Experiment Videos

Last Updated: Mar 16, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.4K
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

17.5K
Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry
08:19

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Published on: May 5, 2022

2.9K

Area of Science:

  • Neuroscience
  • Cell Biology
  • Genetics

Background:

  • Parkinson's disease (PD) is the second leading neurodegenerative disorder, affecting approximately 2% of individuals over 60.
  • Hallmarks of PD include dopaminergic neuron loss in the substantia nigra and Lewy bodies composed of alpha-synuclein.
  • Mitochondrial dysfunction is implicated in both sporadic and familial forms of PD.

Purpose of the Study:

  • To provide a comprehensive review of the mechanisms driving mitochondrial dysfunction in Parkinson's disease.
  • To highlight emerging signaling pathways, such as the retromer-trafficking pathway, involved in PD.
  • To offer an overview of current therapeutic approaches targeting mitochondrial defects in PD.

Main Methods:

  • Literature review focusing on mechanisms of mitochondrial dysfunction in Parkinson's disease.
  • Analysis of genetic and cellular factors contributing to mitochondrial impairment.
  • Examination of novel signaling pathways and therapeutic strategies.

Main Results:

  • Mitochondrial dysfunction in PD arises from bioenergetic deficits, DNA mutations (mtDNA and nuclear DNA), altered mitochondrial dynamics (fusion/fission), impaired trafficking and transport, abnormal morphology, and protein mutations.
  • The retromer-trafficking pathway is identified as a significant signaling pathway implicated in PD pathogenesis.
  • Various therapeutic strategies aim to ameliorate mitochondrial defects in Parkinson's disease.

Conclusions:

  • Mitochondrial dysfunction is a central mechanism in Parkinson's disease.
  • Understanding novel pathways like retromer-trafficking is crucial for PD research.
  • Targeting mitochondrial health offers promising therapeutic avenues for Parkinson's disease.